Speci®c chromosomal translocations are commonly present in mesenchymal tumors and frequently involve genes encoding transcription factors. The combination of dierent domains from unrelated genes results in chimeric proteins believed to play a key role in the neoplastic process. The EWS/ATF1 and EWS/FLI1 fusion proteins associated with Clear Cell Sarcoma and Ewing's Sarcoma, respectively, were utilized to study the comparative eect of the EWS component on two dierent DNA binding partners. A potential regulatory site within the EWS IQ domain at serine266 was identi®ed, and studies were performed to demonstrate that EWS is phosphorylated in cells and phosphorylation of serine266 regulates transcriptional activity. Mutational analysis showed that elimination of phosphorylation signi®cantly reduced DNA binding activity by EMSA and reporter activation in luciferase assays, whereas phosphorylation mimicry resulted in a partial restoration to wild-type levels. Phosphorylation was also observed to mediate cellular compartmentalization. These studies con®rm that IQ domain phosphorylation regulates the transcriptional activity of exogenous EWS/ ATF1 and EWS/FLI1 and suggests that post-translational modi®cations may potentiate the neoplastic behavior of fusion proteins in general. Since the IQ domain is incorporated into only a subset of fusion transcripts, these ®ndings may provide insight into the molecular mechanism underlying clinical heterogeneity observed in Ewing's sarcoma. Oncogene (2001) 20, 1756 ± 1764.
Introduction
Characteristic chromosomal translocations are commonly present in mesenchymal tumors and frequently involve genes encoding transcription factors (Bridge, 1996) . The clonal nature of these genetic abnormalities and their consistent association with speci®c tumor types suggests a possible contribution to neoplastic development (Ladanyi, 1995) . Transcription factors are typically composed of multiple domains having discreet functions, but the combination of dierent domains from unrelated genes through translocation creates fusion proteins having distinctive properties. The alteration in activity of these chimeric proteins potentially disrupts the signaling mechanisms responsible for their regulation. More than twelve dierent combinations of genomic breakpoints of Ewing's Sarcoma protein (EWS) and Friend Leukemia virus Integration site 1 (FLI1) have been described that produce in-frame fusion transcripts. Some of these combinations are associated with worse overall prognosis (de Alava et al., 1998; Lin et al., 1999) . The various EWS/ATF1 and EWS/FLI1 fusion proteins associated with Clear Cell Sarcoma (CCS) and Ewing's Sarcoma (ES) provide the opportunity for studying the regulation of chimeric transcription factors and their contribution to dierent clinical phenotypes.
The unique presence of EWS in multiple tumor associated fusion genes allows for a simultaneous study of its in¯uence upon two dierent DNA binding partners. Though its biological role is not well understood, EWS is known to serve as a TATA-Box Binding Protein (TBP) Associated Factor (TAF) with RNA binding activity (Bertolotti et al., 1998) . Despite an apparent inability to interact with DNA, EWS is also capable of initiating transcription (Pan et al., 1998) . In CCS, translocation t(12;22)(q13;q12) juxtaposes EWS to the gene for Activating Transcription Factor 1 (ATF1) (Bridge et al., 1990 (Bridge et al., , 1991 . ATF1 is a member of the bZIP family of transcription factors that mediate various physiological processes including cellular proliferation, endocrine stimulation and viral pathogenesis (Gilchrist et al., 1995a) . Cyclic AMP and calcium responsive pathways normally regulate ATF1 activity through phosphorylation of its kinase inducible domain (KID) (Gonzalez and Montminy, 1989) . However, in the EWS/ATF1 fusion protein, the amino-terminal activation domain of EWS replaces the KID, rendering it unable to support typical inductive signals (Li and Lee, 1998) . In comparison with CCS, the ES translocation t(11;22)(q24;q12) fuses EWS to FLI1, a helix ± loop ± helix protein belonging to the E-Twenty-Six Transformation Speci®c (ETS) family of transcription factors. ETS factors are important to the development and maturation of numerous mammalian cell lineages (Bassuk and Leiden, 1997) . In the EWS/FLI1 fusion protein, the amino-terminal activation domain of EWS also replaces the FLI1 kinase inducible region. Thus, EWS imparted deregulation of ATF1 and FLI1 may contribute to transcriptional activity and potentiate neoplastic behavior.
In vitro studies have demonstrated that EWS fusion proteins are over-expressed in tumor cells (Bosilevac et al., 1999) , and their transcriptional activation properties are signi®cantly elevated as compared to their native counterparts (Bailly et al., 1994; Fujimura et al., 1996) . EWS/ATF1 and EWS/FLI1 may mediate tumorigenesis through inappropriate activation of ATF1 and FLI1 responsive genes (Li and Lee, 1998) . Studies demonstrating a loss of transforming capacity following selective deletion of the EWS activation domain support its potential contribution to fusion protein activity (May et al., 1993) . We identi®ed a conserved calmodulin binding motif containing an internal Protein Kinase C (PKC) phosphorylation site termed an IQ domain within the EWS portion of the fusion proteins. IQ domains have been well-characterized as regulatory elements in neuronal proteins such as neuromodulin and neurogranin but have not been studied in the context of chimeric transcription factors. Deloulme et al. (1997) recently reported that phosphorylation of serine266 in native EWS in¯uenced its RNA binding properties, but no data are available concerning the phosphorylation status of endogenous EWS/FLI1 or EWS/ATF1 in sarcomas. Thus the IQ domain could represent an important regulatory site for EWS/ATF1 and EWS/FLI1. Studies seeking to investigate the eect of IQ domain phosphorylation on transcriptional activity were undertaken. The IQ domain was altered using a site-directed PCR approach to generate phosphorylation mutant S266A and phosphorylation mimetic S266D proteins. Results using these various mutants in experiments examining DNA binding, transcriptional activation and cellular localization demonstrated that phosphorylation of the EWS IQ domain regulates the EWS/ATF1 and EWS/ FLI1 fusion proteins and suggest that post-translational modi®cations may signi®cantly in¯uence their neoplastic potential.
Results

EWS/ATF1 and EWS/FLI1 are phosphorylated in cells
Transcriptional processes are regulated through a complex cascade of integrated cellular signaling pathways (Hunter and Karin, 1992) . Phosphorylation is a well-established mechanism controlling the activity of transcription factors; however, the eect of posttranslational modi®cations involving chimeric proteins has not been investigated. Previous experiments studying EWS/ATF1 and EWS/FLI1 suggested they may undergo such modi®cations. When mammalian-expressed EWS/ATF1 was compared to protein expressed in E. coli by electrophoretic mobility shift assay (EMSA), an approximate 100-fold dierence in binding strength to the cyclic AMP response element (CRE) cDNA probe was measured (Bosilevac et al., 1999) . Similar dierences were also observed with EWS/FLI1 binding to an ETS oligonucleotide, the consensus binding sequence for FLI1. These observations could be explained by either improper folding or post-translational modi®cations that aect activity since phosphorylation does not occur in bacteria.
To determine whether EWS/ATF1 and EWS/FLI1 are phosphorylated within intact mammalian cells, metabolic labeling studies were performed. EWS fusion proteins were transiently expressed in human embryonic kidney 293T cells incubated in the presence of [ 32 P]-orthophosphate. EWS/ATF1 was immunoprecipitated from nuclear extracts with a cocktail of anti-ATF1 antibodies (Figure 1a ). Whole-cell extracts from EWS/ ATF1, EWS/FLI1 and null-vector expressing cells were also prepared for resolution by SDS ± PAGE and analysed by autoradiography. Distinct bands of the expected size for EWS/ATF1 and EWS/FLI1 were observed among the labeled proteins (Figure 1b) , and band identity was veri®ed by transfer to PVDF membrane and immunoblotting (data not shown). Cells grown in the presence of bisindolylmaleimide, a speci®c inhibitor of PKC, demonstrated a signi®cant reduction in phospho-labeling, and speci®city was con®rmed by comparing cellular extracts incubated with calf intestinal phosphatase (CIP) or heat inactivated CIP (data not shown). CIP treatment resulted in a reduction of EWS/ATF1 and EWS/FLI1 labeling, but denatured CIP had no eect.
Mutagenesis of the EWS IQ domain
To investigate IQ domain regulation of EWS/ATF1 and EWS/FLI1 transcriptional activity, speci®c mutations were inserted into the EWS gene component (Figure 2a ). Serine266 represents the only consensus PKC phosphorylation site in EWS. Isoteric substitution of alanine (S266A) was performed to eliminate the potential regulatory sequence. The concept was further tested by substitution of serine by aspartic acid (S266D) to functionally replace the negative charge of the phosphorylated residue. Metabolic labeling studies demonstrated that IQ domain mutation (S266A) abolished EWS/ATF1 phosphorylation as compared to wild-type ( Figure 2b ). Immunoblots veri®ed equal expression of both proteins (Figure 2c ). DNA sequences of wild-type (WT), phosphorylation mutant (S266A) and phosphorylation mimetic (S266D) clones were veri®ed.
Phosphorylation of serine266 regulates DNA binding activity of EWS/ATF1 and EWS/FLI1
DNA binding represents a key component to the cellular function of transcription factors. To investigate whether IQ domain phosphorylation regulates the DNA binding activity of EWS/ATF1 and EWS/FLI1, electrophoretic mobility shift assays (EMSA) were performed. Extracts from 293T cells transiently expressing wild-type or mutated proteins were normalized for dierences in concentration and incubated in the presence of 32 P-labeled oligonucleotide probes. For these experiments, a CRE (TGACGTCA) as occurs in the somatostatin gene promoter was utilized to study EWS/ATF1, and a consensus ETS sequence (AC-CGGAAGT) was used to probe EWS/FLI1. Following non-denaturing PAGE resolution and autoradiography, shifted complexes were identi®ed by comparison with extracts from null-vector expressing cells. Speci®city of complex formation was demonstrated with the addition of 100-fold excess unlabeled competitor oligonucleotides. Competition with unlabeled CRE resulted in a loss of EWS/ATF1 complex formation but had no eect on EWS/FLI1, whereas competition with unlabeled ETS disrupted EWS/FLI1 complexes but had no eect on EWS/ATF1 (data not shown). Additionally, band identity was veri®ed by supershift experiments using the mAb5 and EWS-N18 (Santa Cruz Biotechnology) antibodies whose epitopes map to the carboxy-terminus of ATF1 and amino-terminus of EWS, respectively. MAb5 supershifted EWS/ ATF1´CRE but had no eect on EWS/FLI1´ETS, whereas both the EWS/ATF1 and EWS/FLI1 complexes were supershifted by EWS-N18 (data not shown). To compare DNA binding activity between the EWS fusion proteins, densitometric analysis of band intensity was utilized as a relative measure. Compared to wild-type, CIP-treated EWS/ATF1 and S266A-EWS/ATF1 bound CRE probe 8.7-fold and 6.7-fold less strongly, respectively (Figure 3a) . Phosphorylation mimicry restored DNA binding by nearly half (2.2-fold) (Figure 3a) . Similarly, CIP treatment of EWS/FLI1 and phosphorylation mutation reduced binding to ETS probe by 5.7-fold and 4.3-fold, respectively (Figure 3a ). S266D-EWS/FLI1 showed DNA binding activity 1.8-fold below the WT level (Figure 3a) . Additionally, cells incubated in the presence of bisindolylmaleimide expressed wild-type EWS/ATF1 and EWS/FLI1 having binding anities comparable to the CIP treated proteins (data not shown). Immunoblots of the cell extracts were performed to verify that observed dierences in DNA binding activity were not due to unequal expression or preferential degradation. No dierence in band intensity was observed between WT, S266A-and S266D-EWS/ATF1 or EWS/FLI1 (Figure 3b) .
Since prokaryotic cells do not perform post-translational modi®cations, the wild-type and phosphorylation mutant forms of EWS/ATF1 and EWS/FLI1 expressed in E. coli were expected to show similar activity in binding studies. No dierence in band intensity was observed between WT or S266A-EWS/ ATF1 and EWS/FLI1 when analysed by EMSA (Figure 3c ). However, phosphorylation mimicry enhanced CRE binding of EWS/ATF1 by 2.4-fold and ETS binding of EWS/FLI1 by 2.2-fold (Figure 3c ). To verify that dierences in DNA binding activity were not due to unequal representation in the respective extracts, the bacterial preparations were immunoblotted. No dierence in band intensity was observed between WT, S266A-and S266D-EWS/ATF1 or EWS/ FLI1 (Figure 3d ).
Phosphorylation of serine266 in cells regulates transcriptional activation of EWS/ATF1 and EWS/FLI1
DNA binding and transcriptional activation are related but distinct activities of transcription factors. Since in vitro binding of EWS/ATF1 and EWS/FLI1 to oligonculeotide probes was regulated by IQ domain phosphorylation, a similar eect on intracellular transactivation was hypothesized. To investigate the eect of serine266, luciferase (luc) reporter assays were performed in 293T cells. Wild-type or mutated EWS/ ATF1 and EWS/FLI1 were studied by co-transfection with either a CRE-luc or an ETS-luc reporter. Roussarcoma virus (RSV)-b-galactosidase controls were used to normalize luciferase results for variations in transfection eciency. Reporter activation by wild-type EWS/ATF1 or EWS/FLI1 was set equal to 1.00. In comparison, phosphorylation mutant EWS/ATF1 reduced reporter activity to 0.53, and phosphorylation mimicry restored activation to 0.77 (Figure 4) . Similarly, the activity of S266A-EWS/FLI1 was 0.61, whereas S266D-EWS/FLI1 restored activation to 0.76 (Figure 4) .
Phosphorylation of serine266 regulates subcellular localization of EWS/ATF1 and EWS/FLI1
Nuclear localization of EWS/FLI1 has been demonstrated previously (Bailly et al., 1994) . One explanation for lower transcriptional activity in mutant EWSproteins is disruption of nuclear transport, so experiments were performed to investigate whether IQ domain phosphorylation regulates subcellular localization. NIH3T3 murine ®broblasts expressing wild-type or mutated constructs were ®xed and immunostained with MAb5 or FLI1-C19 and FITC-conjugated secondary antibody. Wild-type EWS/ATF1 and EWS/ Immunostaining experiments were repeated in the COS1 monkey kidney and HeLa human cervical carcinoma cell lines to determine whether observed dierences in subcellular localization were species or cell-type speci®c phenomena. No dierence was noted (data not shown). As a con®rmatory measure, high salt and low salt extracts of transiently transfected 293T cells representing nuclear and cytoplasmic fractions were analysed by immunoblot assay. Consistent with previous results, wild-type EWS/ATF1 and EWS/FLI1 were found exclusively in nuclear fractions and phosphorylation mutant proteins were equally present in nuclear and cytoplasmic extracts (Figure 7) . Phosphorylation mimicry resulted in a cytoplasmic distribution with partial restoration of the nuclear fraction ( Figure 7 ).
Discussion
Site-speci®c DNA binding proteins such as ATF1 and FLI1 mediate gene expression by recognizing upstream promoter elements and interacting with the transcriptional apparatus. Typically, transcription is regulated through the integration of complex signaling pathways acting upon each component, and posttranslational modi®cations such as phosphorylation represent a signi®cant mechanism controlling these cellular processes. We hypothesized that the distinctly modular restructuring of chimeric transcription factors disrupted their normal regulatory responses. The results presented in this study demonstrate that IQ domain phosphorylation regulates the DNA binding activity, transactivation potential and subcellular localization of EWS/ATF1 and EWS/FLI1. The site of phosphorylation was con®rmed to be in the IQ domain at serine266. Furthermore, the ability of a regulatory domain in one fusion partner to directly aect the functional behavior of the other was de®nitively established.
IQ domain phosphorylation could regulate EWS/ ATF1 and EWS/FLI1 through a number of potential mechanisms including eects upon DNA binding, promotion of protein stability, direction of subcellular localization or induction of transcriptionally favorable intramolecular interactions. Although our EMSA results demonstrate a signi®cant eect of phosphorylation on DNA binding, a direct mechanism is unlikely since native EWS possesses RNA binding but no intrinsic DNA binding activity (Pan et al., 1998) . Since all six fusion proteins studied were present in equal amounts, phosphorylation does not appear to aect protein stability. Subcellular distribution could explain the dierential activity observed between wild-type and mutant protein in reporter assays; however, nuclear localization does not account for the in vitro binding studies. Therefore, it is most likely that IQ domain regulation of transcriptional activity occurs through intramolecular interactions. Phosphorylation may induce a conformation that simultaneously enhances promoter binding and facilitates protein ± protein interactions. In support of such a mechanism, downstream phosphorylation events are known to induce the DNA binding activity of numerous transcription factors (Hunter and Karin, 1992) , and previous studies have demonstrated that the oncogenic potential of Pax3/FKHR in alveolar rhabdomyosarcoma is partially mediated through protein ± protein interactions (Lam et al., 1999) . Native EWS is capable of activating transcription from a variety of promoters when coexpressed with hsRPB7 (Peterman et al., 1998) , and EWS/ATF1 co-precipitates with CREB Binding Protein (CBP) (Fujimura et al., 1996) , also suggesting that EWS may contact other molecules in the transcriptional apparatus. Such interactions could additionally in¯uence nuclear transport. Studies investigating the role of post-translational modi®cations involving other sarcoma-associated fusion proteins such as Pax3/ FKHR would con®rm their contribution to the neoplastic process.
Although individual ES tumors demonstrate single transcript types, at least 12 dierent in-frame chimeric sequences have been observed clinically (May et al., 1993) . Variations in the precise location of chromosomal breakage and reattachment can fuse dierent combinations of exons, and the resulting transcripts are named according to the exons joined. The 7-6 and 7-5 transcripts, also termed types I and II, juxtapose EWS exons 1-7 to FLI1 exons 6-9 and 5-9, respectively, and represent over 85% of all ES tumors. However, in some cases, the fusion transcript incorporates additional portions of EWS including the IQ domain. In vitro studies have demonstrated that the 10-6 transcript is a stronger transactivator than types I or II (Lin et al., 1999) , and clinical studies have shown that transcript type correlates with tumor behavior (de Alava et al., 1998; Zoubek et al., 1994 Zoubek et al., , 1996 . Patients diagnosed with an ES carrying the type I (7-6) transcript have a better prognosis than tumors with a type II transcript. In addition, the presence of EWS exons 8 through 10 have also been associated with a poorer outcome (de Alava et al., 1998; Zoubek et al., 1994 Zoubek et al., , 1996 . Clinical heterogeneity of these latter types could be explained by the presence or absence of the IQ domain since it spans the junction of exons 7 and 8. The recent report that EWS/FLI1 up-regulates phospholipase-Cb in ES cells (Dohjima et al., 2000) suggests that an auto-regulatory loop induces phosphatidylinositol signaling to stimulate PKC activity and potentiates tumorigenesis by further activating the aberrant transcription factor by phosphorylation. Thus, the various clinical phenotypes of ES could be a re¯ection of which fusion transcripts incorporate the IQ domain and may identify potential candidates for gene-based therapies. Previous studies have demonstrated that targeted disruption of CREB/ ATF activity by intracellular expression of inhibitory single-chain antibody fragments (scFv) results in apoptotic death of CCS cells in vitro (Bosilevac et al., 1999) and melanoma cells in vivo (Jean et al., 2000) , and protein kinase inhibitors have been shown to induce regression of numerous tumor types (Caponigro et al., 1997) . Multi-center clinical studies are needed to determine whether presence of the IQ domain has a direct correlation with clinical outcome.
Materials and methods
Construction of EWS/ATF1 and EWS/FLI1 expression plasmids and DNA mutagenesis
Phosphorylation de®cient and mimetic mutants of EWS/ ATF1 were generated using the mega-primer method (Sarkar and Sommer, 1990) with PCR primers encoding changes from serine266 to alanine (S266A) or aspartic acid (S266D). Mega-primers were constructed using RO-D 5'-GGAA-GATCTTCCGGAGAGAAAATGGCGTCCACG-3' and RO-B2/RO-B3 5'-AACCCATGCTACTGGGGTGGTCCT-GTCGGAA-(ACT/GTC)-ACTCTGCTG-3' with pEWS/ ATF1 template (Bosilevac et al., 1998) and paired with RO-C 5'-GAAGATCTTCAAACACTTTTATTGG-3' to amplify full-length mutant cDNA. Wild-type EWS/ATF1 was ampli®ed with RO-D and RO-C. PCR products were ligated into pCRII (Invitrogen), and HindIII/XbaI fragments were inserted into pCMV4. All mutations were veri®ed by DNA sequencing. For expression in E. coli, EcoRI fragments were ligated into pQE41 (Qiagen). For cDNA including EWS exons 1 ± 10, overlapping fragments were generated using RO-D1 and RO-E1 5'-GACTGAGTCATAAGAAGGGT-CCTAGATCAAGATCTGGTCCTTCATCCATGGGTCC-ACCAGGCTTATTGAAGCCACCTCGCTCTCCAGCGC-TGCCCATTCCACCGCGTCCTCC-3' with pCMV-EA-WT, pCMV-EA-S266A or pCMV-EA-S266D template, and RO-F1 5'-GGAATTCGTGAAGGCACGTGGGTGTTA with pEF7-6 (Lin et al., 1999) . Overlapping amplicons were annealed, and second strand synthesis was completed with Klenow fragment (Life Technologies). Full-length EWS/FLI1 cDNA were ampli®ed with RO-D1 and TH-82-2. PCR products were ligated into pCRII and cloned into pCDNA3 using HindIII/XbaI restriction sites and pET32a (Novagen) using NotI/XhoI fragments.
Preparation of recombinant proteins and immunoblot analysis
35
S-labeled and unlabeled EWS/ATF1 and EWS/FLI1 were generated using TnT 1 T7 Quick-Coupled Transcription/ Translation (Promega) for use as markers in immunoblots and EMSA. Recombinant proteins were generated through ispropyl-D-thiogalactopyranoside (IPTG) induction of E. coli BL21 and isolated as insoluble protein fractions (Bosilevac et al., 1999; Zhao and Giam, 1992) . Additionally, EWS/ATF1 and EWS/FLI1 were expressed in transiently transfected 293T cells using LipofectAMINE-PLUS (Life Technologies). Isolation of nuclear, cytoplasmic and whole-cell extracts was performed as described previously (Bosilevac et al., 1999; Orten et al., 1994) , and protein concentrations were calculated by Bradford Assay (Bio-Rad). Comparison of 293T nuclear and cytoplasmic extracts was performed by immunoblotting high and low salt fractions from 10 3 cells. Membranes were incubated with either 1 mg/ml MAb5 followed by alkaline phosphatase (AP)-conjugated goat-anti-mouse, EWS-N18 and AP-mouse-anti-goat or FLI1-C19 and AP-goat-anti-rabbit antibody (SantaCruz Biotechnology) and developed with 5-bromo-4-chloro-3-indolyl-phosphate/nitroblue-tetrazolium substrate. Band intensity was quantitated by densitometry (Kodak Digital Science).
Intracellular phosphorylation of EWS/ATF1 and EWS/FLI1
Metabolic labeling was performed according to established protocols (Fontes et al., 1993; Johnson et al., 1999) . 293T cells expressing EWS/ATF1 or EWS/FLI1 were incubated in phosphate-free DMEM supplemented with 2.0 mCi/ml [ 32 P]-orthophosphate for 5 h. Cells were lysed by freezing in RIPA buer, and clari®ed extracts were resolved by SDS ± PAGE and detected by autoradiography using storage PhosphoImager (Molecular Dynamics). EWS/ATF1 and EWS/FLI1 bands were veri®ed by gel transfer to polyvinylidene di¯uoride (PVDF) membrane (Micron Separations) and immunoblotting.
Electrophoretic mobility shift assay (EMSA) analysis
Electrophoretic mobility shift assay (EMSA) experiments were performed as described previously (Gilchrist et al., 1995b Orten et al., 1994 . Incubation of EWS/ATF1 or EWS/FLI1 protein extracts with 32 P-labeled oligonucleotide probes containing the consensus CRE 5'-AGACATTGCCT-GACGTCAGAGAGCTAG-3' or ETS 5'-ATAAACAG-GAAGTGGT-3' sequences was performed at 48C for 60 ± 120 min. For assays examining 293T-expressed proteins, 1 mg whole-cell extract was included in the reaction mixture. All extracts were incubated in the presence of CIP or HI-CIP for 30 min prior to probe binding. For assays examining E. coli-expressed proteins, 100 mg protein concentrated in a Centricon10 (Amicon) was used, and in experiments directly comparing bacterial and mammalianexpressed proteins, 10 mg whole-cell extract was used. Binding reactions were performed in the presence or absence of MAb5, EWS-N18, FLI1-C19 and isotype-matched control antibodies to verify band identity by super-shifting. Following electrophoresis, bound and unbound fractions of labeled oligonucleotide were detected by autoradiography and quantitated using ImageQuant v5.0 software (Molecular Dynamics).
Luciferase/b-galactosidase assays
Transient co-transfections of 293T cells were performed in triplicate 35 mm culture dishes, and results of three to six experiments were averaged. Co-transfections included 0.75 mg CMV-luc (Bosilevac et al., 1998) or ETS-luc (Lin et al., 1999) and 1.00 mg pCMV-EA-WT, pCMV-EA-S266A, pCMV-EA-S266D, pCDNA-EF-WT, pCDNA-EF-S266A or pCDNA-EF-S266D. To control for variations in transfection eciency, 0.75 mg RSV-b-gal was included as a normalization standard. Cells were harvested 48 h post-transfection by freeze-thaw lysis in potassium phosphate buer, and reporters were assayed. bgalactosidase expression was quantitated with o-nitrophenyl-b-D-galactopyranoside, and absorbance at 405 nm was measured with an ELIZA plate reader (Incstar). Luciferase activity was measured as a function of light emission with a Luminoscan-RS microplate luminometer (Lab Systems).
Immuno-fluorescent cell staining NIH3T3 cells were grown on 25 mm cover glasses (Fisher) and transiently transfected with 1 mg pCMV-EA-WT, pCMV-EA-S266A, pCMV-EA-S266D, pCDNA-EF-WT, pCDNA-EF-S266A, pCDNA-EF-S266D or null vector. Approximately 60 h post-transfection, cells were ®xed with 4% formaldehyde/0.1% glutaraldehyde, permeabilized with 0.3% Triton X-100 and blocked with 1:5000 goat polyclonal antibody (Amersham-Pharmacia) in 5% bovine serum albumin (BSA). EWS/ATF1 was immunostained with MAb5 and¯uorescein-isothiocyanite (FITC)-conjugated anti-mouse antibody. EWS/FLI1 was detected with FLI1-C19 and FITC-anti-rabbit antibody. Covers were mounted on slides with ProLong antifade reagent (Molecular Probes) and viewed with a Nikon Diaphot200 microscope equipped with a SenSys digital camera (Photometrics).
